RAMP For Anthrax Available Before Cardiac Markers – Response Biomedical
This article was originally published in The Gray Sheet
Response Biomedical Corp. will initially target government agencies and public health sites with its Rapid Analyte Measurement Platform (RAMP) anthrax test before fully commercializing the device
You may also be interested in...
Response Biomedical will cut its 36-employee workforce by roughly two-thirds and file for bankruptcy protection to sustain operations over the next several months as it continues to pursue FDA clearance of its RAMP diagnostic system.
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.